BeStock  
Stocks › Biotechnology › FTH

Faeth Therapeutics FTH

US equityMarket cap rank #3739Biotechnology
$7.88 −$0.81 (-9.32%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.88 0.00%
Open$8.52
Prev close$8.69
Day range$7.84 – $9.13
Volume419.1K
Market cap$203.65M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership76.3%+10.27 pts vs. prior quarter
Institutions holding66+15 vs. prior quarter
Insider trades (recent)23 buys / 17 sellsNet buying
Short interest10.57% of floatDays to cover 6.3 · as of 30 Oct 2026
Short-sale volume share18.3%5-day average of daily volume

Short-sale volume as % of daily volume

5%14%23%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$707.7K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

+$1.3MSuper−$544.6KBig−$1.2MMid−$1.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 32.6% of shares outstanding.

Largest holders

  • Khosla Ventures, LLC10.19%
  • Montanova Capital, LLC7.82%
  • Avoro Capital Advisors LLC5.59%
  • Baker Bros. Advisors LP4.98%
  • Balyasny Asset Management L.P.4.03%
  • Cormorant Asset Management, LP3.98%
  • Vanguard Capital Management, LLC3.68%
  • Anand Parikh3.16%

By investor type

  • Hedge Fund45.93%
  • VC/PE Fund16.75%
  • Mutual Fund12.49%
  • Individual/Insider4.27%
  • Private Company0.67%
  • Family Office/Trust0.30%
  • Public Company0.11%
  • Endowment Fund0.04%

Reported short interest has risen from 3.20% to 10.57% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +941,606 3.7%
BlackRock Mutual Fund 2026/Q3 +411,421 1.6%
UBS Asset Management Mutual Fund 2026/Q3 +348,431 1.4%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +319,663 1.2%
State Street Global Advisors Mutual Fund 2026/Q3 +311,427 1.2%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +217,249 0.9%
Montanova Capital, LLC Hedge Fund 2026/Q3 +1,985,554 7.8%
Avoro Capital Advisors LLC Hedge Fund 2026/Q3 +1,444,039 5.6%
Baker Bros. Advisors LP Hedge Fund 2026/Q3 +1,286,411 5.0%
Balyasny Asset Management L.P. Hedge Fund 2026/Q3 +1,025,993 4.0%
Cormorant Asset Management, LP Hedge Fund 2026/Q3 +722,020 4.0%
Fairmount Funds Management LLC Hedge Fund 2026/Q3 +722,020 2.8%
RA Capital Management, L.P. VC/PE Fund 2026/Q3 +722,020 2.8%
Logos Global Management, L.P. Hedge Fund 2026/Q3 +692,020 2.8%
The B Group, Inc. Hedge Fund 2026/Q3 +610,169 2.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Oct 2026 Anand Parikh CEO, President & Chair Other Acquisition +100,000 – 817,699
29 Oct 2026 Anand Parikh CEO, President & Chair Other Disposition -100,000 – 817,699
22 Oct 2026 Adam Schayowitz Director Other Derivative Acquisition +25,000 $17.08 25,000
10 Sep 2026 Karen Vousden Scientific Co-Founder & Director Other Derivative Acquisition +25,000 $37.44 25,000
10 Sep 2026 Karen Vousden Scientific Co-Founder & Director Initial Statement of Beneficial +0 – 42,631
21 Jul 2026 Cambrian BioPharma, Inc. Intent to Sell (Form 144) -130,142 $27.99 –
20 Jul 2026 Anand Parikh CEO, President & Chair Other Derivative Acquisition +398,018 $28.37 398,018
20 Jul 2026 Josiah Craver Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer Other Derivative Acquisition +30,824 $28.37 30,824
30 Jun 2026 Brian Stephenson Chief Financial Officer Open Market Acquisition +13,634 $24.98 46,688
25 Jun 2026 Brian Stephenson Chief Financial Officer Open Market Acquisition +15,641 $27.77 33,054
22 Jun 2026 Brian Stephenson Chief Financial Officer Open Market Acquisition +17,413 $25.91 17,413
21 Jun 2026 Anand Parikh CEO, President & Chair Open Market Acquisition +2,806 $19.76 817,699
21 Jun 2026 Anand Parikh CEO, President & Chair Derivative Exercise and Retained +53,465 $1.16 817,699
14 Jun 2026 Khosla Ventures, LLC Initial Statement of Beneficial +0 – 2,632,232
14 Jun 2026 Stephen Hahn Director Derivative Exercise and Retained +44,763 – 44,763
14 Jun 2026 Anand Parikh CEO, President & Chair Derivative Exercise and Retained +761,428 – 761,428
12 Jun 2026 Brian Stephenson Chief Financial Officer Initial Statement of Beneficial +0 – 166,435
11 Jun 2026 Sona Saira Ramasastry Director Other Derivative Acquisition +25,000 $13.00 25,000
11 Jun 2026 Sona Saira Ramasastry Director Initial Statement of Beneficial +0 – 14,647
11 Jun 2026 Stephen Hahn Director Other Derivative Acquisition +25,000 $13.00 25,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 2,730,889 10.6% 6.3
15 Oct 2026 2,320,706 9.0% 7.8
30 Sep 2026 2,067,445 8.0% 3.6
15 Sep 2026 1,318,893 5.1% 4.4
31 Aug 2026 1,098,324 4.3% 3.7
14 Aug 2026 827,167 3.2% 2.8

Discussion

No comments yet — be the first to weigh in on FTH.

Sign in to join the discussion.

Scroll to Top